Per Wändell1, Axel C Carlsson1,2, Martin J Holzmann3,4, Johan Ärnlöv1,5, Jan Sundquist6,7,8, Kristina Sundquist6,7,8. 1. Division of Family Medicine and Primary Care, Department of Neurobiology, Care Science and Society, Karolinska Institutet, Huddinge. 2. Department of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, Uppsala. 3. Functional Area of Emergency Medicine, Karolinska University Hospital. 4. Department of Internal Medicine, Solna, Karolinska Institutet, Stockholm. 5. School of Health and Social Studies, Dalarna University, Falun. 6. Center for Primary Health Care Research, Lund University, Malmö, Sweden. 7. Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, USA. 8. Center for Community-based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Japan.
Abstract
OBJECTIVE: To study association between relevant cardiovascular pharmacotherapy and incident congestive heart failure (CHF) in patients with atrial fibrillation treated in primary health care. METHODS: Study population included all adults (n = 7975) aged 45 years and older diagnosed with atrial fibrillation at 75 primary care centers in Sweden between 2001 and 2007. Outcome was defined as a first diagnosis of CHF post-atrial fibrillation diagnosis. Association between CHF and treatment with relevant cardiovascular pharmacotherapies (beta blockers, calcium blockers, digitalis, diuretics, RAS blockers, and statins) was explored using Cox regression analysis with hazard ratios and 95% CIs. Adjustments were made for age, sociodemographic variables, and comorbid conditions (with or without cardiovascular disorders). RESULTS: During a mean of 5.7 years (SD 2.3) of follow-up, totally 1552 patients (19.5%; 803 women and 749 men) had a recorded CHF diagnosis. Thiazides (hazard ratio 0.74, 95% CI 0.65-0.84), vessel-active calcium channel blockers (hazard ratio 0.76, 95% CI 0.67-0.86), and nonselective beta blockers (hazard ratio 0.84, 95% CI 0.72-0.98), with specifically sotalol representing 80% of nonselective beta blockers (hazard ratio 0.81, 95% CI 0.69-0.97), were associated with lower CHF risk in fully adjusted models. Loop diuretics (hazard ratio 1.41, 95% CI 1.25-1.57) were associated with a higher risk. Findings for thiazides and vessel-active channel blockers were consistent in the tested subgroups. CONCLUSION: In this clinical setting, we found that thiazides, vessel-active calcium channel blockers, and nonselective beta blockers (specifically sotalol) were associated with a lower risk of incident CHF among patients with atrial fibrillation. The findings of the present study need to be confirmed in other settings.
OBJECTIVE: To study association between relevant cardiovascular pharmacotherapy and incident congestive heart failure (CHF) in patients with atrial fibrillation treated in primary health care. METHODS: Study population included all adults (n = 7975) aged 45 years and older diagnosed with atrial fibrillation at 75 primary care centers in Sweden between 2001 and 2007. Outcome was defined as a first diagnosis of CHF post-atrial fibrillation diagnosis. Association between CHF and treatment with relevant cardiovascular pharmacotherapies (beta blockers, calcium blockers, digitalis, diuretics, RAS blockers, and statins) was explored using Cox regression analysis with hazard ratios and 95% CIs. Adjustments were made for age, sociodemographic variables, and comorbid conditions (with or without cardiovascular disorders). RESULTS: During a mean of 5.7 years (SD 2.3) of follow-up, totally 1552 patients (19.5%; 803 women and 749 men) had a recorded CHF diagnosis. Thiazides (hazard ratio 0.74, 95% CI 0.65-0.84), vessel-active calcium channel blockers (hazard ratio 0.76, 95% CI 0.67-0.86), and nonselective beta blockers (hazard ratio 0.84, 95% CI 0.72-0.98), with specifically sotalol representing 80% of nonselective beta blockers (hazard ratio 0.81, 95% CI 0.69-0.97), were associated with lower CHF risk in fully adjusted models. Loop diuretics (hazard ratio 1.41, 95% CI 1.25-1.57) were associated with a higher risk. Findings for thiazides and vessel-active channel blockers were consistent in the tested subgroups. CONCLUSION: In this clinical setting, we found that thiazides, vessel-active calcium channel blockers, and nonselective beta blockers (specifically sotalol) were associated with a lower risk of incident CHF among patients with atrial fibrillation. The findings of the present study need to be confirmed in other settings.
Authors: K H Humphries; C R Kerr; S J Connolly; G Klein; J A Boone; M Green; R Sheldon; M Talajic; P Dorian; D Newman Journal: Circulation Date: 2001-05-15 Impact factor: 29.690
Authors: Björn Wettermark; Niklas Hammar; Carl Michael Fored; C MichaelFored; Andrejs Leimanis; Petra Otterblad Olausson; Ulf Bergman; Ingemar Persson; Anders Sundström; Barbro Westerholm; Måns Rosén Journal: Pharmacoepidemiol Drug Saf Date: 2007-07 Impact factor: 2.890
Authors: Per Wändell; Axel C Carlsson; Xinjun Li; Martin J Holzmann; Jan Sundquist; Kristina Sundquist Journal: J Clin Hypertens (Greenwich) Date: 2020-07-15 Impact factor: 3.738
Authors: Min Zhao; Mark Woodward; Ilonca Vaartjes; Elizabeth R C Millett; Kerstin Klipstein-Grobusch; Karice Hyun; Cheryl Carcel; Sanne A E Peters Journal: J Am Heart Assoc Date: 2020-05-20 Impact factor: 5.501